<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01618253</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00017344</org_study_id>
    <nct_id>NCT01618253</nct_id>
  </id_info>
  <brief_title>Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma</brief_title>
  <official_title>Phase I Study of Radiation Therapy With Concurrent Sorafenib for Hepatocellular Carcinoma Not Responding to Transarterial Chemoembolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated radiation dose with concurrent sorafenib for unresectable&#xD;
      hepatocellular carcinoma that has not responded to transarterial chemoembolization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with unresectable hepatocellular carcinoma (HCC), transarterial chemoembolization&#xD;
      (TACE) is first line therapy. Non-responders to TACE (i.e. stable or progressive disease)&#xD;
      represent a poor prognosis population with limited options. Sorafenib is indicated for first&#xD;
      line salvage therapy, however it only improves survival 2-3 months and just has a 2-3%&#xD;
      response rate. Thus, sorafenib is merely a cytostatic agent that delays progression and does&#xD;
      not cytoreduce disease.&#xD;
&#xD;
      Radiation therapy (RT) is a non-invasive treatment that can cytoreduce HCC with minimal&#xD;
      morbidity using modern techniques. A meta-analysis and multiple retrospective series suggest&#xD;
      TACE + RT improve survival when compared to TACE alone. Higher RT doses are similarly&#xD;
      associated with increased survival due to improved local control. Paradoxically, some series&#xD;
      suggest that RT can induce vascular endothelial growth factor (VEGF) expression which may&#xD;
      stimulate HCC.&#xD;
&#xD;
      Pre-clinical data suggest that combining RT with concurrent sorafenib (a VEGF inhibitor)&#xD;
      improves tumor control. However, clinical data is limited to case reports and safety has not&#xD;
      been well characterized. Prior to determining if this combination can improve control of HCC&#xD;
      in this poor prognosis population, the optimal radiation dose with concurrent sorafenib must&#xD;
      be determined by a phase I dose escalation trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Closed due to poor accrual.&#xD;
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>From date of enrollment until 3 months after completion of treatment.</time_frame>
    <description>Maximum tolerated dose (MTD) will be determined by dose limiting toxicity (DLT) that is observed in either the acute (during treatment) or subacute (up to 3 months after treatment) setting. Acute DLT will be defined by grade 3-5 hepatic, gastrointestinal, dermatologic, hematologic, or pulmonary toxicity per Common Toxicity Criteria for Adverse Effects (CTCAE), v4.0. Subacute DLT will be defined by radiation induced liver disease (RILD) or grade 3-5 gastrointestinal, hematologic, or pulmonary toxicity per CTCAE, v4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic Response</measure>
    <time_frame>1 &amp; 3 months post-treatment.</time_frame>
    <description>Evaluated by either contrast enhanced MRI (preferred) or CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of Failure</measure>
    <time_frame>From date of enrollment until the date of first documented progression, last known folow-up, or date of death from any cause, whichever came first, assessed up to 10 years.</time_frame>
    <description>Classified as local (in-field), regional (intrahepatic out-of-field), or distant (extrahepatic, which includes porta hepatic lymph nodes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From date of enrollment until the date of first documented progression, last known folow-up, or date of death from any cause, whichever came first, assessed up to 10 years.</time_frame>
    <description>From date of enrollment until first local, regional, or distant failure following RT, last follow-up, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of enrollment until the date of last known folow-up or date of death from any cause, whichever came first, assessed up to 10 years.</time_frame>
    <description>From date of enrollment until last follow-up or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>1, 2, &amp; 3 months post-treatment.</time_frame>
    <description>FACT-Hep survey will be utilized to establish pre-treatment baseline and then compared to post-treatment evaluations at months 1, 2, and 3.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatocellular Cancer</condition>
  <condition>Hepatoma</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation therapy with concurrent sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.</description>
    <arm_group_label>Radiation therapy with concurrent sorafenib</arm_group_label>
    <other_name>Sorafenib Tosylate</other_name>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional fractionation (2 Gy per day) external beam radiation therapy</intervention_name>
    <description>Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or &gt;10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If &gt;1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.&#xD;
The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions &gt;10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced.</description>
    <arm_group_label>Radiation therapy with concurrent sorafenib</arm_group_label>
    <other_name>External Beam Radiation Therapy</other_name>
    <other_name>Radiation Therapy</other_name>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Radiographic or histologic diagnosis of hepatocellular carcinoma (HCC).&#xD;
&#xD;
          -  Maximum of 3 HCC lesions within the liver.&#xD;
&#xD;
          -  No evidence of lymphadenopathy or metastatic disease per either CT or PET.&#xD;
&#xD;
          -  Prior transarterial chemo-embolization (TACE) at least 28 days prior to initiation of&#xD;
             protocol therapy.&#xD;
&#xD;
          -  Evidence of either progressive disease or stable disease following TACE.&#xD;
&#xD;
          -  Child Pugh Class A (score 5-6) or B (score 7).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1 (or Karnofsky ≥70%).&#xD;
&#xD;
          -  Normal organ and marrow function (platelets &gt;60,000/mc; hemoglobin ≥8.5 g/dL;&#xD;
             international normalized ratio (INR) ≤2.3; albumin ≥2.8 g/dL; total bilirubin ≤3&#xD;
             mg/dL; aspartate aminotransferase (AST) / alanine aminotransferase (ALT) &lt;5x upper&#xD;
             limit of normal; creatinine ≤1.5x upper limit of normal).&#xD;
&#xD;
          -  Negative human immunodeficiency virus serology.&#xD;
&#xD;
          -  Negative pregnancy test for women of child bearing age.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 800 cc of normal liver.&#xD;
&#xD;
          -  Child Pugh Class B (score 8-9) or C (score 10-15).&#xD;
&#xD;
          -  Acute/active hepatitis B infection.&#xD;
&#xD;
          -  Prior systemic chemotherapy or abdominal radiation therapy.&#xD;
&#xD;
          -  Portal venous (main, primary right, or primary left trunks) or inferior vena cava&#xD;
             thrombosis.&#xD;
&#xD;
          -  Prior malignancy within 5 years of enrollment except for non-melanoma skin cancer.&#xD;
&#xD;
          -  Prior history of myocardial infarction, cerebrovascular accident, or esophageal&#xD;
             variceal bleed in the last 6 months.&#xD;
&#xD;
          -  Pre-existing heart failure with either a clinical classification of New York Heart&#xD;
             Association Class III or IV or cardiac ejection fraction of &lt;45%.&#xD;
&#xD;
          -  Systolic blood pressure &gt; 160 mmHg or diastolic pressure &gt; 100 mmHg despite optimal&#xD;
             medical management.&#xD;
&#xD;
          -  Pulmonary hemorrhage or other serious bleeding event (grade 2+) within 4 weeks&#xD;
             initiation of protocol therapy.&#xD;
&#xD;
          -  Prior history of scleroderma or active systemic lupus erythematosus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth A. Erickson-Wittmann, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert Memorial Lutheran Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chung YL, Jian JJ, Cheng SH, Tsai SY, Chuang VP, Soong T, Lin YM, Horng CF. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006 May 1;12(9):2706-15.</citation>
    <PMID>16675562</PMID>
  </reference>
  <reference>
    <citation>Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, Diehl JA, Smith CD, Flaherty KT, El-Deiry WS. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007 Oct 1;67(19):9443-54.</citation>
    <PMID>17909054</PMID>
  </reference>
  <reference>
    <citation>Ren ZG, Zhao JD, Gu K, Chen Z, Lin JH, Xu ZY, Hu WG, Zhou ZH, Liu LM, Jiang GL. Three-dimensional conformal radiation therapy and intensity-modulated radiation therapy combined with transcatheter arterial chemoembolization for locally advanced hepatocellular carcinoma: an irradiation dose escalation study. Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):496-502. doi: 10.1016/j.ijrobp.2009.10.070. Epub 2010 Apr 24.</citation>
    <PMID>20421145</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2012</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transarterial Chemoembolization</keyword>
  <keyword>TACE</keyword>
  <keyword>Sorafenib Tosylate</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Nexavar</keyword>
  <keyword>External Beam Radiation Therapy</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

